In the high-stakes world of biotechnology, taking a company public is as much a test of leadership as it is a validation of science. For Leen Kawas, co-founder and former CEO of Athira Pharma, leading a $400 million initial public offering in 2020 was the culmination of years spent navigating the unpredictable terrain of drug development, investor relations, and corporate growth. It also marked a rare achievement—placing her among only 22 women founders in the United States to take a company public.
Kawas’s path to the IPO began not on Wall Street, but in the laboratory. A trained scientist and inventor, she built her career around the belief that breakthroughs in science mean little unless they can be translated into therapies that reach patients. That conviction drove her leadership style at Athira, shaping how she aligned science, strategy, and capital to create a biotech company capable of making the leap to the public markets.
From Scientific Vision to Business Strategy
When Kawas co-founded Athira Pharma, the company’s mission was clear: develop treatments that could slow or reverse neurodegenerative diseases like Alzheimer’s and Parkinson’s. The scientific challenge was formidable, with high failure rates in the field and significant capital requirements for late-stage clinical trials.
Kawas understood early that scientific promise alone would not secure the resources needed to advance Athira’s drug candidates. She positioned the company to attract sophisticated investors by articulating a clear path from discovery to commercialization. This meant building credibility through robust preclinical data, designing clinical trials with regulatory rigor, and demonstrating a deep understanding of the market opportunity.
By marrying scientific depth with a disciplined business plan, Leen Kawas created a narrative that resonated with both biotech specialists and generalist investors.
Building Investor Confidence
Raising capital in biotech requires more than a good story—it requires sustained engagement and trust-building. Kawas cultivated relationships with venture capitalists, institutional investors, and strategic partners, ensuring that each understood Athira’s milestones and risks.
Her investor outreach was marked by transparency. She communicated setbacks as well as successes, framing challenges as part of the process rather than as crises. This approach reinforced confidence in her leadership and in the company’s ability to navigate the inherent uncertainty of drug development.
As Athira advanced its clinical programs into later stages, Kawas knew that the company’s financing needs would exceed what private markets could reliably provide. The decision to pursue an IPO was not just about raising capital; it was about positioning Athira for long-term growth, broadening its investor base, and increasing its visibility in the highly competitive biotech sector.
Timing and Execution
The IPO market in 2020 was unusually active, with investor appetite for biotech deals running high despite the global economic disruption of the COVID-19 pandemic. Kawas and her team recognised this as a strategic window. They moved decisively to prepare Athira for a public offering, working with underwriters to refine the company’s value proposition and prepare the necessary disclosures.
The preparation process required intense coordination between Athira’s scientific, regulatory, and financial teams. Every data point had to be accurate, every risk factor articulated, every growth opportunity substantiated. Kawas’s role was to keep these efforts aligned, ensuring that the IPO pitch was both scientifically credible and commercially compelling. This interview on Billion Success explores insights from Kawas further.
The Roadshow and Investor Response
The IPO roadshow—traditionally a whirlwind of in-person meetings—was conducted largely virtually due to pandemic restrictions. Kawas adapted to the format, delivering Athira’s story with clarity and focus over video calls to investors around the world. She highlighted the company’s differentiated approach to neurodegenerative disease, the progress of its lead drug candidates, and the broader market need.
The response was strong. Investors were drawn not only to the scientific potential but also to the disciplined way Kawas had managed Athira’s growth. When the IPO priced, it raised over $400 million—capital that would allow the company to accelerate its clinical programs and expand its research pipeline.
Impact and Legacy
Athira’s IPO was more than a financial milestone; it was a statement about what is possible when scientific expertise is matched with strategic leadership. The capital raised positioned the company to compete in one of the most challenging areas of drug development, giving it the resources to pursue therapies that could change the trajectory of devastating diseases.
For Kawas personally, the achievement reinforced her reputation as a leader capable of guiding a biotech company from inception to the public markets. It also highlighted the broader need for diversity in biotech leadership, where women—and particularly women founders—remain underrepresented at the CEO level.
Lessons for Future Biotech Leaders
Kawas’s experience offers several takeaways for others in the industry:
- Align science and strategy early. A promising technology is not enough; it must be framed within a credible commercial plan.
- Build trust through transparency. Long-term investor relationships are built on honest communication, especially about challenges.
- Move when the market is ready. The timing of an IPO can significantly affect its outcome; readiness must be matched with market conditions.
- Lead across disciplines. Successful biotech leaders bridge science, finance, regulation, and operations with equal fluency.
By leading Athira to a $400 million IPO, Leen Kawas demonstrated that scientific vision, when matched with strategic execution, can unlock the capital needed to pursue ambitious goals. It is a model that continues to influence how she approaches her work at Propel Bio Partners—supporting other innovators in translating science into solutions that reach the patients who need them most.
To learn more about what Leen Kawas is currently up to, check out Inherent Bio.
Leave a Reply